Cantor Fitzgerald Has Negative View of HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Harmony Biosciences in a note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of $2.19 per share for the year, down from their prior estimate of $2.68. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences’ FY2026 earnings at $1.94 EPS.

Several other equities research analysts have also recently commented on HRMY. Mizuho boosted their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, May 15th. Wall Street Zen lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday. Oppenheimer initiated coverage on shares of Harmony Biosciences in a research note on Monday, June 2nd. They set an “outperform” rating and a $61.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They set a “neutral” rating and a $33.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $55.00 price target (up previously from $54.00) on shares of Harmony Biosciences in a research note on Thursday, July 10th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $34.19 on Friday. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of 11.03, a P/E/G ratio of 0.42 and a beta of 0.84. Harmony Biosciences has a twelve month low of $26.47 and a twelve month high of $41.61. The company’s fifty day moving average is $34.16 and its 200-day moving average is $33.80. The company has a quick ratio of 3.63, a current ratio of 3.84 and a debt-to-equity ratio of 0.20.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%. The company’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.05 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Financial Management Professionals Inc. acquired a new position in shares of Harmony Biosciences during the 1st quarter worth approximately $29,000. Brooklyn Investment Group grew its position in shares of Harmony Biosciences by 1,031.9% during the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock worth $35,000 after purchasing an additional 970 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Harmony Biosciences by 4,185.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock worth $37,000 after purchasing an additional 1,130 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $41,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Harmony Biosciences during the 1st quarter worth approximately $57,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.